Eli Lil­ly’s alope­cia drug Olu­mi­ant off to pos­i­tive start with doc­tors, Spher­ix re­search finds

Eli Lil­ly’s alope­cia area­ta drug is off to a good start with der­ma­tol­o­gists. So good, in fact, that the launch of Olu­mi­ant in alope­cia looks a lot like the ini­tial pos­i­tive launch of Sanofi and Re­gen­eron’s Dupix­ent, ac­cord­ing to launch track­ing da­ta from Spher­ix Glob­al In­sights.

Spher­ix bench­marked Olu­mi­ant against Dupix­ent’s launch ap­proval in atopic der­mati­tis in part be­cause there are no oth­er can­di­dates in alope­cia, said Gi­an­na Me­len­dez, who heads der­ma­tol­ogy at Spher­ix. Olu­mi­ant al­so com­pares sim­i­lar­ly to Dupix­ent as a first bi­o­log­ic in the cat­e­go­ry, along with an ac­com­pa­ny­ing lev­el of ex­cite­ment and buzz around it.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.